Seo Jung-Jin, chairman of Celltrion Group, said in a New Year's address on Jan. 2 that "the three years from this year to 2028 will be a period to lay the groundwork for a quantum leap (rapid growth)," adding, "We will introduce an artificial intelligence (AI) platform across the business."
Seo said, "As AI is changing the industrial landscape, we must push forward with strategic decisions to prepare for the future," adding, "We will produce future results in step with these new changes." She then said, "Like 'Jeokdoma (Red Hare),' I will run alongside employees and in the field."
The company plans to use an AI platform to improve efficiency in drug development, clinical trials, manufacturing, and sales. It will expand its business beyond pharmaceuticals into Digital Healthcare. It will establish a dedicated organization for new investments and set up subsidiaries in India and China. It plans to secure local talent in bio and IT.
Seo said, "For biosimilars (biosimilar), we will expand the portfolio from the current 11 products at the commercialization stage to 40 within about 10 years." For new drugs, the company plans to expand from four that entered clinical trials last year to 20. It will expand production capacity by adding facilities at home and abroad.